Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on CymaBay Therapeutics (CBAY) on March 12 and set a price target of $4.00. The company’s shares closed last Monday at $1.47, close to its 52-week low of $1.29.
According to TipRanks.com, Archila ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.7% and a 33.3% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Pacira Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CymaBay Therapeutics with a $4.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.89 and a one-year low of $1.29. Currently, CymaBay Therapeutics has an average volume of 1.6M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
